Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ryan Gentzler, MD
Summary
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent. 3. ECOG Performance Status of 0-1 within 28 days prior to registration. 4. Confirmation of stage IV non-small cell lung cancer (NSCLC) per AJCC, 8th edition, or metastatic recurrence after treatment for earlier stage disease. 5. Known to have a KRAS G12C mutation. KRAS G12C mutation can be determined based on local tissue and/o…
Interventions
- DrugAdagrasib
Adagrasib 600mg orally
- RadiationStereotactic Radiosurgery
Delivered as per standard of care
Locations (3)
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio
- University of Virginia Health SystemCharlottesville, Virginia
- Virginia Commonwealth UniversityRichmond, Virginia